Fluvoxamine

cytochrome P450 family 2 subfamily C member 19 ; Homo sapiens







45 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33806634 Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network. 2021 Mar 4 2
2 33302490 A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. 2020 Dec 8 1
3 30902567 Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype. 2019 Apr 1
4 26886336 Dynamic and Static Simulations of Fluvoxamine-Perpetrated Drug-Drug Interactions Using Multiple Cytochrome P450 Inhibition Modeling, and Determination of Perpetrator-Specific CYP Isoform Inhibition Constants and Fractional CYP Isoform Contributions to Victim Clearance. 2016 Mar 1
5 27002781 The Effects of Fluvoxamine on the Steady-State Plasma Concentrations of Escitalopram and Desmethylescitalopram in Depressed Japanese Patients. 2016 Aug 3
6 25689244 Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial. 2015 Feb 1
7 25719307 Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland. 2015 Sep 1
8 24855828 Identification of CYP2C19 inhibitors from phytochemicals using the recombinant human enzyme model. 2014 May 1
9 21277363 Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. 2011 Apr 10 1
10 18691982 Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. 2008 Jul 1
11 17307149 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. 2007 Apr 6 1
12 17431033 Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. 2007 Jul 1
13 17596106 Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide. 2007 3
14 16487224 Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status. 2006 Mar 3
15 15963095 Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine. 2005 Jul 3
16 15025747 Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. 2004 Apr 3
17 15199661 Some aspects of genetic polymorphism in the biotransformation of antidepressants. 2004 Jan-Feb 2
18 15319333 CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes. 2004 Sep 1
19 15496639 Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes. 2004 Nov 3
20 12695344 Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. 2003 May 4
21 14703714 Metabolic drug interactions with new psychotropic agents. 2003 Oct 1
22 11876575 Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. 2002 Feb 1
23 11907488 Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). 2002 Mar 3
24 12038880 Clinically significant drug interactions with antidepressants in the elderly. 2002 1
25 12222750 Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype. 2002 3
26 12452751 Fluvoxamine interaction with warfarin. 2002 Dec 1
27 11519155 [Pharmacokinetics and drug interactions of antidepressive agents]. 2001 Aug 1
28 10674711 Pharmacokinetics of selective serotonin reuptake inhibitors. 2000 Jan 1
29 10877005 Fluvoxamine but not citalopram increases serum melatonin in healthy subjects-- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. 2000 May 2
30 11038165 Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. 2000 Nov 1
31 11085201 Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. 2000 Oct 1
32 10587283 Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. 1999 Dec 1
33 9923577 Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. 1998 Nov-Dec 4
34 9174682 Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. 1997 2
35 9184622 Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. 1997 1
36 9333103 Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. 1997 Sep 3
37 9353355 Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. 1997 Nov 1
38 8880055 Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. 1996 3
39 8904628 In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. 1996 Oct 3
40 8968657 Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. 1996 Dec 1
41 8986013 Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. 1996 Dec 1
42 9032002 Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. 1996 Dec 1
43 7622807 Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. 1995 Mar 1
44 8846618 Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6. 1995 1
45 8846622 Drug interactions and the cytochrome P450 system. The role of cytochrome P450 2C19. 1995 1